The Leader in Combination Product Services

WUXI APPTEC WUXI APPTEC

A Leading Pharmaceutical, Biotech and Medical Device R&D Outsourcing Company with a Global Platform

Note: (1) Current good manufacturing practice

Shanghai, ChinaHeadquarters

Laboratory services, consisting of synthetic and medicinal chemistry, DMPK/ADME, biology, microbiology, In Vivo pharmacology, toxicology, pharmaceutical development, analytical services, biopharmaceutical, in vitro and in vivo biocompatibility testing and efficacy testingManufacturing services, focusing on advanced intermediates, active pharmaceutical ingredients (APIs), and biologics-based manufacturing, testing and related services

Service Offerings

4,142 employees (3,721 in China and 421 in the US)Employees

~ 2.0 million sq. ft. lab, animal facilities and manufacturing spaceChina:► 1 million ft² total research facilities in Shanghai and Tianjin► 291,000 ft² total cGMP(1) quality process development and manufacturing facilities in

Shanghai► 314,000 ft² drug safety evaluation center in Suzhou United States:► 208,000 ft² total three state-of-the-art FDA-registered facilities in St. Paul, Philadelphia

and Atlanta

Facilities

Over 800 clients worldwide including 110 for pharmaceutical services and 700 for biologics, combination product and device services100% repeat business from top 10 customers

Customers

2

Facilities in the U.S.Facilities in the U.S.• 83,000 ft² FDA-registered facility for in vitro and in vivo biocompatibility, toxicology, contract

cGMP manufacturing and processing for tissue-based products, in St. Paul, US• 50,000 ft² FDA-registered facility for microbiology, medical device chemistry, sterilization

validations, package testing in Atlanta, US• 75,000 ft² FDA-registered facility for process development, cGMP manufacturing of cell banks

and cellular therapeutics, cell biology, molecular biology, virology, analytical services, viral clearance studies in Philadelphia, US

Philadelphia Atlanta St. Paul

3

Approximately 1,000,000 ft² R&D facility for chemistry, bio-analytical, discovery biology, DMPK and process research in Shanghai, China253,000 ft² R&D facility for chemistry in Tianjin, China293,000 ft² cGMP-quality process development and manufacturing plant in Shanghai, China22,000 ft² cGMP-quality formulation pilot plant in Shanghai, China58,000 ft² large- and small-animal facilities currently in operation (China and US)314,000 ft² GLP pre-clinical drug safety testing facility in Suzhou, China

Shanghai

Tianjin Suzhou

Jinshan, Shanghai

GLP pre‐clinical drug safety testing 

Facilities in ChinaFacilities in China

• 82,000 ft² FDA-registered facility for in vitro and in vivo biocompatibility, toxicology, contract cGMP manufacturing and processing for tissue-based products, in St. Paul, US

• 314,000 ft² GLP pre-clinical drug safety testing facility in Suzhou, China

St. Paul Suzhou

PrePre--Clinical Testing FacilitiesClinical Testing Facilities

WuXi AppTec Service PortfolioWuXi AppTec Service Portfolio

Guidance and Services Across Therapeutic DeliveriesMedical Device

• Testing Programs• Cell Therapy and Specialty Ortho Bio Manufacturing

Biologics • Testing Programs

Pharmaceutical• Laboratory Discovery Services• Development and Manufacturing Services

Convergence

Combination Products

Combination Products

Services & Guidance to Meet Regulatory RequirementsServices & Guidance to Meet Regulatory Requirements

WX Combination Product PlatformsWX Combination Product Platforms